Natera, Inc. (NASDAQ:NTRA) Insider John Fesko Sells 663 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 663 shares of Natera stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the transaction, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

John Fesko also recently made the following trade(s):

• On Monday, December 23rd, John Fesko sold 669 shares of Natera stock. The shares were sold at an average price of $159.60, for a total transaction of $106,772.40.

Natera Stock Performance

Natera stock opened at $172.82 on Friday. The stock’s fifty day simple moving average is $167.56 and its 200-day simple moving average is $140.02. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $67.33 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.95) EPS. On average, analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NTRA. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Barclays started coverage on shares of Natera in a report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Craig Hallum boosted their price objective on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, The Goldman Sachs Group raised their price objective on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $165.88.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning lifted its holdings in shares of Natera by 28.3% in the 2nd quarter. Creative Planning now owns 4,929 shares of the medical research company’s stock valued at $534,000 after purchasing an additional 1,087 shares during the last quarter. Sanctuary Advisors LLC purchased a new position in Natera in the second quarter valued at about $380,000. Park Avenue Securities LLC raised its stake in shares of Natera by 14.7% during the 3rd quarter. Park Avenue Securities LLC now owns 7,833 shares of the medical research company’s stock worth $994,000 after buying an additional 1,005 shares during the last quarter. GAMMA Investing LLC lifted its stake in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares in the last quarter. Finally, CWM LLC boosted its stake in shares of Natera by 119.5% during the 3rd quarter. CWM LLC now owns 15,441 shares of the medical research company’s stock worth $1,960,000 after purchasing an additional 8,406 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.